ImmunityBio Management
Management Kriterienprüfungen 3/4
ImmunityBio CEO ist Rich Adcock , ernannt in Oct 2020, hat eine Amtszeit von 5.75 Jahren. Die jährliche Gesamtvergütung beträgt $12.72M , bestehend aus 6.5% Gehalt und 93.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.054% der Aktien des Unternehmens, im Wert von $5.29M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5 Jahre bzw. 5.9 Jahre.
Wichtige Informationen
Rich Adcock
Geschäftsführender
US$12.7m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 6.54% |
| Amtszeit als Geschäftsführer | 5.8yrs |
| Eigentum des Geschäftsführers | 0.05% |
| Durchschnittliche Amtszeit des Managements | 5yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 5.9yrs |
Jüngste Management Updates
Recent updates
IBRX: Potential Index Inclusion Will Support Cancer Franchise Expansion
Analysts have lowered their ImmunityBio price target slightly from $13.50 to $13.00 as they refresh assumptions around discount rates, revenue growth, margins, and future P/E expectations. What’s in the News for ImmunityBio Retail traders are speculating that ImmunityBio stock could shift from the Russell 2000 to the Russell 1000 based on a cutoff around US$5.7b, with some traders expecting potential index fund buying and changes in volatility if inclusion occurs, according to recent Stocktwits sentiment data and after hours trading moves.ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout
Summary ImmunityBio is transitioning into a scalable bladder cancer immunotherapy platform, driven by accelerating Anktiva adoption and robust revenue growth. 1Q26 revenue surged 168% YoY to $44.2M, with strong physician uptake, but operating expenses and adjusted net loss ($86.2M) remain elevated amid heavy investment. The papillary sBLA for Anktiva is a key near-term catalyst; regulatory uncertainty persists, but compelling QUILT-3.032 data and prior FDA approval in CIS support optimism. The Tokyo-172 BCG deal positions IBRX to resolve U.S. supply bottlenecks, enabling dual-source BCG infrastructure and global expansion, enhancing platform value. Read the full article on Seeking AlphaHere's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results
Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...
Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?
Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
NasdaqGS:IBRX 1 Year Share Price vs Fair Value Explore ImmunityBio's Fair Values from the Community and select yours A...ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking AlphaImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking AlphaImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
Summary ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but recent product sales and supportive financing extend the cash runway, providing a potential growth opportunity. Strengths include data supporting new approvals and expanding Anktiva's market, though risks involve unclear lung cancer market size and significant liabilities. Upgrading IBRX stock to “Buy” due to likely 2025 catalysts: accelerating Anktiva sales, potential lung cancer approval, and expanding bladder cancer market. Read the full article on Seeking AlphaAnalyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$855m |
| Dec 31 2025 | US$13m | US$832k | -US$351m |
| Sep 30 2025 | n/a | n/a | -US$349m |
| Jun 30 2025 | n/a | n/a | -US$367m |
| Mar 31 2025 | n/a | n/a | -US$409m |
| Dec 31 2024 | US$11m | US$802k | -US$414m |
| Sep 30 2024 | n/a | n/a | -US$588m |
| Jun 30 2024 | n/a | n/a | -US$598m |
| Mar 31 2024 | n/a | n/a | -US$601m |
| Dec 31 2023 | US$1m | US$796k | -US$583m |
| Sep 30 2023 | n/a | n/a | -US$458m |
| Jun 30 2023 | n/a | n/a | -US$473m |
| Mar 31 2023 | n/a | n/a | -US$430m |
| Dec 31 2022 | US$4m | US$791k | -US$417m |
| Sep 30 2022 | n/a | n/a | -US$400m |
| Jun 30 2022 | n/a | n/a | -US$376m |
| Mar 31 2022 | n/a | n/a | -US$370m |
| Dec 31 2021 | US$29m | US$765k | -US$347m |
| Sep 30 2021 | n/a | n/a | -US$323m |
| Jun 30 2021 | n/a | n/a | -US$301m |
| Mar 31 2021 | n/a | n/a | -US$264m |
| Dec 31 2020 | US$843k | US$141k | -US$222m |
Vergütung im Vergleich zum Markt: RichDie Gesamtvergütung ($USD12.72M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD14.46M).
Entschädigung vs. Einkommen: RichDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Rich Adcock (57 yo)
Mr. Richard Gerald Adcock, also known as Rich, has been the President of ImmunityBio, Inc. since March 05, 2021 and serves as its Director since March 29, 2021. He has been the Chief Executive Officer of I...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder | 11.7yrs | US$12.29m | 27.83% $ 2.8b | |
| President | 5.8yrs | US$12.72m | 0.053% $ 5.3m | |
| Chief Financial Officer | 7yrs | US$4.24m | 0.029% $ 2.8m | |
| Chief Accounting Officer | 4.7yrs | US$745.31k | 0.011% $ 1.1m | |
| Chief Corporate Affairs Officer & Director | 5.3yrs | keine Daten | 0.27% $ 26.5m | |
| Chief Technology Officer | 3.5yrs | keine Daten | keine Daten | |
| Chief Communications Officer & Head of Patient Advocacy | 6.3yrs | keine Daten | keine Daten | |
| Senior Vice President of Human Resources | 5yrs | keine Daten | keine Daten | |
| Chief Medical Officer of Liquid Tumors & Cell Therapy | 1.4yrs | keine Daten | keine Daten | |
| Chief Medical Officer | 5.9yrs | keine Daten | keine Daten | |
| Chief Science Officer of Cellular | no data | keine Daten | keine Daten | |
| Senior VP of Product Development & Cell Therapy Program | 2.5yrs | keine Daten | keine Daten |
Erfahrenes Management: Das Managementteam von IBRX ist erfahren und erfahren (durchschnittliche Amtszeit von 5 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder | 11.7yrs | US$12.29m | 27.83% $ 2.8b | |
| President | 5.3yrs | US$12.72m | 0.053% $ 5.3m | |
| Chief Corporate Affairs Officer & Director | 19.5yrs | keine Daten | 0.27% $ 26.5m | |
| Independent Director | 5.9yrs | US$477.28k | 0% $ 0 | |
| Independent Director | 5.4yrs | US$470.59k | 0.00076% $ 75.1k | |
| Independent Director | less than a year | US$302.74k | keine Daten | |
| Independent Director | 11yrs | US$513.38k | 0.025% $ 2.5m | |
| Lead Independent Director | 7.1yrs | US$514.19k | 0.019% $ 1.9m | |
| Independent Director | 5.3yrs | US$489.19k | 0% $ 0 |
Erfahrener Vorstand: IBRXDie Vorstandsmitglieder gelten als erfahren (5.9 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/05 07:38 |
| Aktienkurs zum Tagesende | 2026/07/02 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
ImmunityBio, Inc. wird von 6 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |